)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Entrada Therapeutics (TRDA) investor relations material
Entrada Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Advanced clinical-stage programs for Duchenne muscular dystrophy (DMD), with three candidates (ENTR-601-44, ENTR-601-45, ENTR-601-50) in or approaching clinical trials by year-end 2025, and a fourth (ENTR-601-51) in preclinical development.
First patient dosed in ELEVATE-45-201; data from initial cohorts of ELEVATE-44-201 and ELEVATE-45-201 expected in 2026.
Vertex partnership continues with ongoing global Phase 1/2 trial for VX-670 in myotonic dystrophy type 1 (DM1), with enrollment and dosing on track for completion in H1 2026.
Cash, cash equivalents, and marketable securities totaled $326.8 million as of September 30, 2025, expected to fund operations into Q3 2027.
Strategic workforce reduction of 20% implemented to focus resources on DMD and key preclinical programs, incurring a $1.9 million charge in 2025.
Financial highlights
Collaboration revenue was $1.6 million for Q3 2025, down from $19.6 million in Q3 2024, due to completion of research plan activities for VX-670.
Net loss for Q3 2025 was $44.1 million, compared to a net loss of $14.0 million in Q3 2024.
For the nine months ended September 30, 2025, collaboration revenue was $24.1 million (down from $173.4 million in 2024), and net loss was $104.6 million (compared to net income of $64.5 million in 2024).
Research and development expenses increased to $38.4 million in Q3 2025 (from $31.3 million in Q3 2024), and to $108.3 million for the nine months ended September 30, 2025 (from $91.9 million in 2024).
General and administrative expenses were $10.3 million in Q3 2025 and $31.5 million for the nine months ended September 30, 2025.
Outlook and guidance
Cash runway expected to last into Q3 2027 based on current operating plans.
Anticipates increased R&D expenses as clinical programs advance, particularly for DMD franchise and preclinical pipeline.
Data from ELEVATE-44-201 Cohort 1 expected in Q2 2026; ELEVATE-45-201 Cohort 1 data expected mid-2026.
Plans to initiate additional clinical studies for DMD candidates in the U.S. and EU in 2026, including regulatory filings for ENTR-601-50 and ENTR-601-51.
ELEVATE-44-102 Phase 1b study in the U.S. planned for H1 2026.
Future revenue impact of VX-670 research completion
DMC's basis for ELEVATE-44-201 continuation
Strategic importance of ocular pipeline expansion
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Entrada Therapeutics earnings date
Q4 20256 Mar, 2026
Next Entrada Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular sites traditionally considered unreachable by conventional therapies. The company's proprietary Endosomal Escape Vehicle technology facilitates the efficient intracellular delivery of diverse therapeutic modalities, including RNA, antibodies, and enzymes. This approach is being applied to develop treatments for a range of diseases, particularly in neuromuscular, ocular, metabolic, and immunological areas. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage